US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi U.S. Healthcare 2x Daily ETF

33.10

+0.91392.84%

Volume:2K

Turnover:64.18K

Market Cap:662.00K

PE:- -

High:33.11

Open:33.11

Low:33.10

Close:32.19

52wk High:35.56

52wk Low:25.40

Shares:20.00K

Float Shares:20.00K

Volume Ratio:7.76

T/O Rate:9.70%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Look for Big Changes in Medicare Enrollment

CVS Stock Dips After Drop in Medicare Advantage Plan Ratings

Humana is the 'Biggest Winner' From CMS' Medicare Advantage Star Ratings Impact on 2028 Reimbursements, Oppenheimer Says

MT Newswires Live

Humana Says 95% of Its Medicare Advantage Members in Plans With at Least 4 Stars for 2027

MT Newswires Live

Teva announces FDA approval for Weltruza

Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027

Humana Stock Surges After Key Medicare Advantage Plan Gets Higher Rating

Aetna Has About 70% of Medicare Advantage Members in Four-Star-or-Better 2027 Plans, CVS Health Says

Alignment Healthcare Slides After a Medicare Advantage Contract Gets 3.5-Star Rating

Clover Health up over 8% after-hours following CMS Star Ratings update

Medicare Open Enrollment Starts Next Week. Why It's Really Important to Shop This Year.

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

Humana (HUM), Why Is It Back In The Spotlight?

Simply Wall St.

Clover Health’s 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value

Medicare Advantage Plans Will be Cheaper Next Year. Here's the New Cost.

Medicare Advantage Plans Will be Cheaper Next Year. Here's the New Cost.

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M

EBR Systems advances FDA approval process for new WiSE manufacturing site

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/XLVX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"XLVX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVX\",,,,,undefined,":{"symbol":"XLVX","market":"US","secType":"STK","nameCN":"Corgi U.S. Healthcare 2x Daily ETF","latestPrice":33.1,"timestamp":1791576000000,"preClose":32.1861,"halted":0,"volume":1940,"delay":0,"changeRate":0.02839424472054701,"floatShares":20000,"shares":20000,"eps":0,"marketStatus":"Market Closed","change":0.9139,"latestTime":"10-09 16:00:00 EDT","open":33.11,"high":33.11,"low":33.1,"amount":64182,"amplitude":0.000311,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":32.1861,"nav":32.17,"aum":643400,"bidAskSpread":0,"volumeRatio":7.7599956544024336},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVX\",,,,,undefined,":{"symbol":"XLVX","floatShares":20000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":7.7599956544024336,"shares":20000,"dividePrice":0,"high":33.11,"amplitude":0.000311,"preClose":32.1861,"low":33.1,"week52Low":25.3968,"pbRate":"--","week52High":35.56,"institutionHeld":0,"latestPrice":33.1,"eps":0,"divideRate":0,"volume":1940,"delay":0,"ttmEps":0,"open":33.11,"prevYearClose":25.46,"prevWeekClose":31.5253,"prevMonthClose":32.5588,"prevQuarterClose":32.5588,"fiveDayClose":31.5253,"twentyDayClose":31.1534,"sixtyDayClose":30.3159},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XLVX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XLVX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XLVX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XLVX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674583898","title":"Look for Big Changes in Medicare Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2674583898","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674583898?lang=en_us&edition=fundamental","pubTime":"2026-10-10 09:30","pubTimestamp":1791595800,"startTime":"0","endTime":"0","summary":"Medicare's annual open enrollment period begins Oct. 15, and beneficiaries may find fewer options as carriers scale back their plans.Market contractions cut across Medicare Advantage, the privately ru","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","UNHG","LU0266013472.USD","LU0208291251.USD","FXH","LU0211331839.USD","LU0348723411.USD","LU0170899867.USD","BK4154","XLVX","SG9999014013.SGD","BK4533","LNGR","BK4566","LU0417517546.SGD","LU0390134368.USD","BK4585","LU1093756168.USD","IYH","HUM","LU0256863811.USD","IHF","SG9999014021.USD","UNHU","LU0238689110.USD","LU0320765489.SGD","UN","IEHS","UNHW","LU0070302665.USD","LU1093756325.SGD","XHS","BK4588","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674647848","title":"CVS Stock Dips After Drop in Medicare Advantage Plan Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=2674647848","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674647848?lang=en_us&edition=fundamental","pubTime":"2026-10-10 05:27","pubTimestamp":1791581220,"startTime":"0","endTime":"0","summary":"Shares of CVS Health fell Friday after its insurance arm Aetna lost ground in the latest ratings of Medicare Advantage plans for seniors.The stock lost 1.87%, closing at $86.16, while peer Humana, whi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HUM","UNHU","XHS","LNGR","XLVX","IEHS","IHF","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674865101","title":"Humana is the 'Biggest Winner' From CMS' Medicare Advantage Star Ratings Impact on 2028 Reimbursements, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2674865101","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674865101?lang=en_us&edition=fundamental","pubTime":"2026-10-10 00:46","pubTimestamp":1791564368,"startTime":"0","endTime":"0","summary":"Humana  is the \"overwhelming\" winner from the Centers for Medicare & Medicaid Services' Medicare Advantage Star Ratings impact on 2028 reimbursements, Oppenheimer said in a Thursday research report.CMS released Star Ratings affecting 2028 reimbursement, with 4+ Star Rating membership exposure at 71% compared with 64% a year earlier, analysts wrote.The brokerage estimated that with 95% of Humana members in 4+ Star plans, the difference will account for over $3.6 billion in revenue for the company, resulting in around $20 in EPS if not passed through to bids, according to the note.Humana's membership-weighted average Star Rating grew from 53% to 95%, driven by a rebound in the national contract, according to Oppenheimer.The brokerage said it reiterated its outperform rating on the stock and increased its price target to $475 per share from $405.Price: 434.65, Change: +47.53, Percent Change: +12.28","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IHF","XLVX","XHS","00867","UNHU","IYH","IEHS","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674886870","title":"Humana Says 95% of Its Medicare Advantage Members in Plans With at Least 4 Stars for 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2674886870","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674886870?lang=en_us&edition=fundamental","pubTime":"2026-10-09 23:13","pubTimestamp":1791558825,"startTime":"0","endTime":"0","summary":"Price: 435.16, Change: +48.04, Percent Change: +12.41","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UNHU","XLVX","LU1093756325.SGD","LU0417517546.SGD","LU0320765489.SGD","XHS","UNHG","LU0211331839.USD","LNGR","UN","SG9999014005.SGD","HUM","IEHS","LU0170899867.USD","LU0256863811.USD","BK4588","LU0266013472.USD","UNHW","LU1983260115.SGD","LU1093756168.USD","LU0070302665.USD","IHF","BK4566","BK4154","SG9999014013.SGD","LU0390134368.USD","BK4533","IYH","FXH","LU0348723411.USD","SG9999014021.USD","BK4585","LU0238689110.USD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674785642","title":"Teva announces FDA approval for Weltruza","url":"https://stock-news.laohu8.com/highlight/detail?id=2674785642","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674785642?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:05","pubTimestamp":1791543924,"startTime":"0","endTime":"0","summary":"Teva (TEVA) announced that the FDA has approved Weltruza for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","LFSC","TEVA","MRNY","GDOC","BK4588","BK4566","BK4007","IYH","XLVX","BBP","BK4596","IDNA","MEDI","TECB","BMED","LABU","NVIB","BK4557","IBB","LU2324357040.USD","FRTY","BK4584","IEIH","SYNB","GNMX","TBXU","RSPH","LU1983299246.USD","PINK","BK4559","BK4585","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674885693","title":"Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2674885693","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674885693?lang=en_us&edition=fundamental","pubTime":"2026-10-09 06:45","pubTimestamp":1791499500,"startTime":"0","endTime":"0","summary":"Star ratings support Clover’s continued ability to offer market-leading and low out-of-pocket costs for membersWILMINGTON, Del., Oct.  08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Na","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/08/3377770/0/en/clover-health-medicare-advantage-ppo-plans-earn-5-star-rating-for-2027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XHS","IYH","LNGR","IHF","UNHU","HUM","XLVX","IEHS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674855158","title":"Humana Stock Surges After Key Medicare Advantage Plan Gets Higher Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2674855158","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674855158?lang=en_us&edition=fundamental","pubTime":"2026-10-09 06:45","pubTimestamp":1791499500,"startTime":"0","endTime":"0","summary":"Humana stock gained 13% in after hours trading Thursday after the federal government released new ratings data on Medicare Advantage plans, showing that Humana achieved a four-star rating on a key con","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Humana Stock Surges After Key Medicare Advantage Plan Gets Higher Rating","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XHS","IYH","LNGR","IHF","HUM","IEHS","UNHU","XLVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674488588","title":"Aetna Has About 70% of Medicare Advantage Members in Four-Star-or-Better 2027 Plans, CVS Health Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2674488588","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674488588?lang=en_us&edition=fundamental","pubTime":"2026-10-09 06:34","pubTimestamp":1791498840,"startTime":"0","endTime":"0","summary":"CVS Health's health-insurance company Aetna said that more 69% of its Medicare Advantage members are in 2027 plans rated four stars or higher by the government.The Centers for Medicare & Medicaid Services evaluates insurance plans based on a five-star rating system every year.Aetna received five stars for its care for older adults medication review and 4.03 stars for its care for older adults functional status assessment, CVS Health said.On plan all-cause readmissions, which tracks the percentage of patient hospital stays followed by an unplanned readmission, received 4.77 stars, the company said.Aetna has above four-star ratings for its rate of complaints about the drug plan, customer service and rating of healthcare quality, CVS Health said.Shares of the company slipped 2.7%, to $85.47, after hours Thursday after closing about flat, at $87.80.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072461881.USD","LU0266013472.USD","LU1571399168.USD","IE0002270589.USD","BK4154","LU0256863811.USD","SG9999014021.USD","LU0211331839.USD","LU0417517546.SGD","UNHG","IYH","AET","IE00B19Z3B42.SGD","XHS","LU0390134368.USD","LNGR","LU0070302665.USD","LU0061475181.USD","LU1923622614.USD","LU0238689110.USD","IE00BSNM7G36.USD","FXH","LU2433249047.HKD","BK4196","LU0170899867.USD","LU0348723411.USD","UNHU","BK4550","LU1059921491.USD","LU1093756325.SGD","LU0208291251.USD","BK4533","BK4504","BK4585","LU0859254822.USD","UN","HUM","LU2125909247.SGD","BK4588","SG9999014013.SGD","UNHW","CVS","LU1236620834.HKD","IEHS","RTH","IHF","XLVX","LU0432979614.USD","IE00BZ1G4Q59.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674883515","title":"Alignment Healthcare Slides After a Medicare Advantage Contract Gets 3.5-Star Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2674883515","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674883515?lang=en_us&edition=fundamental","pubTime":"2026-10-09 05:42","pubTimestamp":1791495720,"startTime":"0","endTime":"0","summary":"Shares of Alignment Healthcare fell after one of its 2027 Medicare Advantage contracts received a 3.5-star rating from the Centers for Medicare & Medicaid Services, according to the company.The stock slipped 21%, to $6.90, after-hours Thursday. It closed 1.9% higher, at $8.71, but has fallen 56% this year.The 3.5-star rating, part of CMS's annual ratings of Medicare Advantage plans, was given to the company's California H3815 HMO contract.\"Alignment believes the rating does not accurately reflect the contract's longstanding performance on evidence-based measures of quality, clinical outcomes and member experience,\" the company said.Dawn Maroney, the chief executive officer of Alignment Health Plan, said the company supports measuring the quality of health plans but called into question CMS's methodology.\"We intend to pursue all available administrative remedies and to litigate the measures and methodologies we believe warrant review,\" she said.\"At the same time, our strategy remains un","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IHF","IYH","LNGR","HUM","XHS","XLV","ALHC","XLVX","IEHS","UNHU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674279888","title":"Clover Health up over 8% after-hours following CMS Star Ratings update","url":"https://stock-news.laohu8.com/highlight/detail?id=2674279888","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674279888?lang=en_us&edition=fundamental","pubTime":"2026-10-09 05:15","pubTimestamp":1791494115,"startTime":"0","endTime":"0","summary":"Shares of Clover Health (CLOV) are up 8.5% after-hours at $4.97 after the release of 2027 Medicare Advantage and Part D Star Ratings that boosted C...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clover-health-up-over-8-after-hours-following-cms-star-ratings-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clover-health-up-over-8-after-hours-following-cms-star-ratings-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","FXH","LU0208291251.USD","BK4585","XLVX","LU0238689110.USD","IEHS","LU0348723411.USD","SG9999014013.SGD","LU0070302665.USD","HUM","LU0256863811.USD","LU0170899867.USD","LU0417517546.SGD","LU1983260115.SGD","CLOV","LU0211331839.USD","LU0320765489.SGD","LU1093756168.USD","UN","IYH","LU0266013472.USD","LU1093756325.SGD","BK4154","XHS","IHF","SG9999014021.USD","UNHU","LNGR","BK4533","BK4547","BK4588","UNHG","SG9999014005.SGD","LU0390134368.USD","UNHW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702989","title":"Medicare Open Enrollment Starts Next Week. Why It's Really Important to Shop This Year.","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702989","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702989?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:00","pubTimestamp":1791442800,"startTime":"0","endTime":"0","summary":"Medicare's annual open enrollment period begins Oct. 15, and beneficiaries may find fewer options as carriers scale back their plans.Market contractions cut across Medicare Advantage, the privately ru","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNHU","LU0238689110.USD","UN","LU0211331839.USD","LU1093756325.SGD","IEHS","UNHW","LU0208291251.USD","SG9999014013.SGD","IYH","LU0256863811.USD","SG9999014021.USD","BK4588","BK4585","IHF","LNGR","BK4533","LU0170899867.USD","LU0266013472.USD","LU0320765489.SGD","LU1093756168.USD","XLVX","LU0070302665.USD","BK4154","BK4566","LU0348723411.USD","XHS","HUM","LU1983260115.SGD","SG9999014005.SGD","UNHG","FXH","LU0417517546.SGD","LU0390134368.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011517","title":"Novartis announces FDA approval of Rhapsido for symptomatic dermographism","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011517","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011517?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:50","pubTimestamp":1791388212,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that the Food and Drug Administration approved Rhapsido as the first treatment for adults with symptomatic dermographism i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","MEDX","LU0070302665.USD","XLVX","NVIB","LU0208291251.USD","IE00BJT1NW94.SGD","BMED","LFSC","IYH","LABU","FRTY","BK4585","BK4588","BBP","BK4007","MEDI","IEIH","TECB","GNMX","PINK","BK4578","MRNY","LU0320765489.SGD","IE0002141913.USD","IBB","SYNB","TBXU","GDOC","IDNA","BK4532","MRNX","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0211331839.USD","RSPH","NVS","IE00BJJMRZ35.SGD","PPH","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673118620","title":"Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673118620","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673118620?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:45","pubTimestamp":1791387900,"startTime":"0","endTime":"0","summary":"In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible ur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376686/0/en/novartis-rhapsido-remibrutinib-receives-fda-approval-as-first-treatment-for-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IAI","LU1064131342.USD","LU1720051108.HKD","LU0210528500.USD","LU1668664300.SGD","LU0528227936.USD","LU0267386448.USD","MEDI","PINK","LU2089284900.SGD","PSCH","KBWB","LU2357305700.SGD","LU2487616109.SGD","SD","TBXU","TECB","BK4581","LFSC","MRNX","LABU","BK4585","LU1720051017.SGD","LU0390134368.USD","NVIB","FRTY","IBB","BK4504","LU0912757837.SGD","BBP","LU1791710582.SGD","IEIH","LU2028103732.USD","BMED","MRNY","XLVX","LU1244550221.USD","LU0795875169.SGD","SYNB","RSPH","LU2023251221.USD","GDOC","LU2264538146.SGD","IE00BZ1G4Q59.USD","LU0106831901.USD","IE00B3S45H60.SGD","LU1989772840.SGD","IYH","GNMX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672779757","title":"Humana (HUM), Why Is It Back In The Spotlight?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672779757","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672779757?lang=en_us&edition=fundamental","pubTime":"2026-10-02 13:27","pubTimestamp":1790918866,"startTime":"0","endTime":"0","summary":"Humana (HUM) just outlined its 2027 Medicare Advantage lineup, highlighting $0 in-network primary care and labs, dental, vision and hearing benefits, and an expanded footprint for chronic condition special needs plans.\nHumana’s latest Medicare Advantage refresh lands after a strong run, with the share price up 43.56% year to date and a 1 year total shareholder return of 49.57%, although the 3 year and 5 year total shareholder returns remain in decline. This suggests recent momentum is...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/29618-card/1789197611380","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/29618-card/1789197611380"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-hum-why-is-it-back-in-the-spotlight","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-hum-why-is-it-back-in-the-spotlight","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0266013472.USD","BK4154","LU0256863811.USD","HUM.AU","SG9999014021.USD","LU0211331839.USD","LU0417517546.SGD","SG9999014005.SGD","UNHG","BK7500","IYH","XHS","LU0390134368.USD","LNGR","LU0070302665.USD","LU0238689110.USD","FXH","LU0170899867.USD","LU0348723411.USD","UNHU","LU1093756325.SGD","LU0208291251.USD","LU1983260115.SGD","BK4533","UN","BK4585","HUM","SG9999014013.SGD","BK4588","BK7093","BK4566","LU0320765489.SGD","UNHW","IEHS","IHF","XLVX","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672754056","title":"Clover Health’s 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2672754056","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672754056?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:00","pubTimestamp":1790856000,"startTime":"0","endTime":"0","summary":"Clover’s portfolio combines high-choice PPO access and meaningful member benefits with a Clover Assistant-powered care modelWILMINGTON, Del., Oct.  01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investmen","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372826/0/en/clover-health-s-2027-medicare-advantage-plans-emphasize-ppo-choice-preventive-care-and-member-value.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNHU","UNHW","CGCV","LNGR","XLVX","IE00BN29S564.USD","IE00BJJMRY28.SGD","IHF","FNCL","FDFF","STBQ","LU2552382058.USD","XLF","IXJ","LU0950375773.USD","CLOV","IYH","LU0345770993.USD","CHH","UNHG","IE00B4JS1V06.HKD","BK4559","IE000F7OJYX1.SGD","LU0320765059.SGD","LU0316494557.USD","MA","UYG","XHS","VHT","HUM","LU0061474960.USD","LU0210536198.USD","IEHS","FXH","LU0868494617.USD","IE00B775H168.HKD","BK4534","LU0210533765.USD","LU0276348264.USD","UN","LU2404859667.USD","IPAY","NOBL","LATR","IYG","TCAF","LU2552382132.HKD","LU2462157665.USD","CA","VFH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672816387","title":"Medicare Advantage Plans Will be Cheaper Next Year. Here's the New Cost.","url":"https://stock-news.laohu8.com/highlight/detail?id=2672816387","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672816387?lang=en_us&edition=fundamental","pubTime":"2026-10-01 02:03","pubTimestamp":1790791380,"startTime":"0","endTime":"0","summary":"Medicare beneficiaries can change their coverage during open enrollment, which begins Oct. 15Medicare Advantage currently controls more than half of the overall Medicare market of roughly 69.6 million","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","LU0238689110.USD","SG9999014013.SGD","HUM","LU0256863811.USD","IHF","LU0320765489.SGD","XHS","UNHW","LU0070302665.USD","LU0208291251.USD","IYH","LNGR","BK4154","UNHU","LU0390134368.USD","LU1093756325.SGD","BK4588","LU0348723411.USD","FXH","LU0417517546.SGD","UN","XLVX","BK4533","LU0211331839.USD","LU1093756168.USD","LU1983260115.SGD","IEHS","BK4566","SG9999014021.USD","BK4585","UNHG","LU0170899867.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671431772","title":"Medicare Advantage Plans Will be Cheaper Next Year. Here's the New Cost.","url":"https://stock-news.laohu8.com/highlight/detail?id=2671431772","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671431772?lang=en_us&edition=fundamental","pubTime":"2026-09-29 23:17","pubTimestamp":1790695020,"startTime":"0","endTime":"0","summary":"Medicare beneficiaries can change their coverage during open enrollment, which begins Oct. 15Medicare Advantage currently controls more than half of the overall Medicare market of roughly 69.6 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IHF","LU0238689110.USD","LU0348723411.USD","SG9999014013.SGD","BK4585","IYH","UNHG","BK4588","UNHU","LU1093756168.USD","BK4533","LU0170899867.USD","XLVX","LU0320765489.SGD","LU0211331839.USD","LU1983260115.SGD","LU0070302665.USD","HUM","IEHS","LNGR","UN","SG9999014005.SGD","LU0256863811.USD","LU0417517546.SGD","UNHW","XHS","FXH","LU1093756325.SGD","LU0208291251.USD","SG9999014021.USD","LU0266013472.USD","LU0390134368.USD","BK4154"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671125702","title":"Teva announces FDA approval of Degevma as a biosimilar to Xgeva","url":"https://stock-news.laohu8.com/highlight/detail?id=2671125702","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671125702?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625914,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceutical Industries announced that the FDA has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","FRTY","BK4585","BK4559","MRNX","IDNA","XLVX","IBB","MEDI","BK4557","BBP","LU1983299246.USD","BK4007","RSPH","LABU","IYH","LU2324357040.USD","TBXU","LFSC","PSCH","BMED","TECB","TEVA","IEIH","GNMX","BK4588","BK4584","GDOC","SYNB","MRNY","PINK","NVIB","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670236928","title":"Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670236928?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:10","pubTimestamp":1790590220,"startTime":"0","endTime":"0","summary":"With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. FDA approval of Ziihera for first-line HER2-positive advanc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","BK4588","TECB","LABU","MRNX","XLVX","TBXU","PSCH","BK4007","PINK","GDOC","IEIH","BK4585","IYH","BMED","RSPH","LFSC","TBPH","BBP","MEDI","IBB","NVIB","SYNB","MRNY","FRTY","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402990","title":"EBR Systems advances FDA approval process for new WiSE manufacturing site","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402990","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402990?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:08","pubTimestamp":1790554084,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:EBR) ). EBR Systems, developer of the WiSE wi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","TECB","FRTY","MRNX","EES","IBB","MEDI","IDNA","NVIB","TBXU","PINK","BMED","GNMX","GDOC","SYNB","BBP","BK4588","LABU","LFSC","IYH","RSPH","BK4585","PSCH","IEIH","XLVX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":81,"code":"91000000","status":"200"}]}}